No Data
No Data
There's Reason For Concern Over Nektar Therapeutics' (NASDAQ:NKTR) Massive 26% Price Jump
Nektar Therapeutics' (NASDAQ:NKTR) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 13% Over the Past Week
Rodman & Renshaw Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $2
Oppenheimer Maintains Nektar Therapeutics(NKTR.US) With Hold Rating
Nektar Therapeutics(NKTR.US) Director Sells US$23,400 in Common Stock
Express News | Nektar Therapeutics - Ind-Enabling Studies Underway for Nktr-0165 With First-in-Human Studies Planned in First Half of 2025